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CASE REPORT Open Access
Long-term outcomes of destructive
seronegative (rheumatoid) arthritis –
description of four clinical cases
Elena Nikiphorou1, Christopher Sjöwall2, Pekka Hannonen1, Tuomas Rannio1 and Tuulikki Sokka1,3*
Abstract
Background: Seronegative rheumatoid arthritis is associated with a milder course of progression compared
to seropositive disease. However, long-term follow-up data of the clinical course of seronegative rheumatoid
arthritis are sparse. Here we describe four cases with a rare disease entity of aggressive destructive
seronegative (rheumatoid) arthritis with 20-35 years of follow-up.
Case presentation: The four cases are women with an initial presentation of seronegative rheumatoid arthritis in
1980-1996 and have received disease-modifying anti-rheumatic drugs since the diagnosis. In all cases, the
condition has been refractory to treatments and evolved into a severe disease with destructions of the wrists,
sub-talar and ankle joints, as well as large joints but not small joints of fingers and toes. All cases are
negative with regard to rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antibodies against
carbamylated proteins.
Conclusions: This report adds to the existing literature, making the reader aware of this sub-type of
inflammatory arthritis which despite being seronegative, can have devastating disease consequences. The
report highlights the need for further research into this field in order to better understand this disease
sub-type, the pathogenesis, disease course and outcomes.
Keywords: Rheumatoid arthritis, Seronegative, Erosions, Outcomes
Background
Classification criteria for rheumatoid arthritis (RA)
have evolved over the decades. Positive serology
receives special emphasis in the current criteria [1].
In addition to rheumatoid factor (RF) and anti-cyclic
citrullinated peptide (aCCP) antibodies, other RA-
related antibodies have recently been identified. These
include antibodies against carbamylated proteins
(aCarP) [2] and malonaldehyde-acetaldehyde [3], albeit
none of these are currently included in classification
criteria or used in routine clinical practice.
Autoantibodies are believed to have a pathogenetic
role in RA [4]. In studies examining predictors,
associating factors, or prevention of RA, seropositive
and seronegative groups of patients seem to behave
differently [5–7]. In treatment recommendations for
RA, seropositivity is recognized as an indicator of se-
vere disease and in these patients, the thresholds for
earlier and more intensive/potent disease-modifying
treatment are lower [8]. It has become increasingly
apparent that our knowledge concerning the patho-
genesis, treatment responses and clinical course of
seronegative RA, is limited [9, 10].
Up to 20-30 % of patients recruited into RA
cohorts and clinical trials are seronegative [11, 12].
An exception is the Finnish Heinola Rheumatism
Foundation Hospital early RA cohort from the middle
1970’s, which included long-term (25 years) follow-up of
seropositive patients only, as experienced rheumatologists
were convinced that seropositive disease (positive RF
alone at that time) is the only true presentation of
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the disease [13]. This formed the basis of our interest
in observing the clinical presentation of seronegative
RA.
Observations in our early RA cohorts indicate that
long-term radiographic outcomes are different be-
tween seropositive and seronegative patients [14].
The natural course of seropositive disease is that of
progressive erosions [15], while even in the long-
term (e.g. over 20 years), seronegative patients do
not present with marked erosions [16]. However,
among >3000 patients included in the Jyvaskyla Cen-
tral Hospital clinical RA database since the 1990’s
we identified a few consistently RF and aCCP nega-
tive individuals with a particular presentation of
aggressive, destructive disease. Four cases are pre-
sented in detail herein.
Fig. 1 a Initial clinical presentation of Patient 1. b Progress of Patient 1. c 1-5. Most recent radiographs of Patient 1 (16-19 years from diagnosis)
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Case presentation
Case 1
Demographics: 68 year old female, diagnosed at the
age of 50 in 10.1996. Shopkeeper, work disabled since
the diagnosis; former smoker.
Initial presentation: Swelling and tenderness starting
in the right knee in 01.1996. Intra-articular gluco-
corticoid injections administered into the right knee
four times, until arthroscopy in 08.1996 with macro-
and microscopic finding of synovitis. Joint symptoms
gradually evolved resulting in the diagnosis of clin-
ical polyarthritis in 10.1996. See Fig. 1a.
Comorbidities and Joint surgery: See Table 1.
Medications: Current medications, see Table 1. Previ-
ous synthetic and biologic disease modifying anti rheum-
atic drug (DMARD) treatments were (in order of use):
sulfasalazine, gold intra muscular (IM), podofyllotoxin
(Reumacon), ciclosporin, cyclosphosphamide, lefluno-
mide, infliximab, azathioprine, and hydroxychloroquine,
see Fig. 1b.
Progress: See Fig. 1b. Most recent values for patient
reported outcomes and disease activity: HAQ 1.63,
pain 35, fatigue 6, patient global 30, ESR 16, CRP 2,
DAS28 3.4 indicating moderate disease activity.
Radiographic features: Radiographs on presentation
showed no joint damage. The most recent radio-
graphs of hands, wrists, feet, and ankles, taken 16-19
years after diagnosis, are shown in Fig. 1c. Prominent
features include joint space narrowing and sublux-
ation of bones in left wrist and meta carpo phalangeal
MCP joints, destruction and operation of subtalar,
talonavicular and naviculo-cuneiforme joints, as well
as right ankle. Typical erosions, seen as in seroposi-
tive RA patients are missing.
Case 2
Demographics: 39 year old female, diagnosed at the
age of 16 in 07.1992. Working as a civil engineer.
Never smoked.
Initial presentation: The patient sustained a left
knee strain while running in 3.1992; symptoms
spontaneously resolved within 3 weeks. She was noted
to have hyperextension of the left knee in 6.1992 with
7.1992 with synovial fluid aspiration showing 14.000
leucocytes (98 % granulocytes) and a clinical presenta-
tion of polyarthritis as shown in Fig. 2a.
Comorbidities and Joint surgery: See Table 2.
Medications. Current medications see Table 2. Pre-
vious DMARD treatments included (in order of use):
i.m. gold, sulphasalazine, podofyllotoxin (Reumacon),
hydroxychloroquine, infliximab, and rituximab see
Fig. 2b.
Progress: See Fig. 2b. Most recent values for patient
reported outcomes and disease activity: HAQ 0.13,
pain 8, fatigue 12, patient global 9, ESR 2, CRP 5,
DAS28 2.1 indicating remission.
Radiographic features: Initial joint radiographs on
presentation showed no damage. The most recent
radiographs 20-23 years after diagnosis are presented
in Fig. 2c. The prominent features are damage in
wrists, subluxation of right MCP II, damage of talona-
vicular and naviculo-cuneiform joints, but minimal
erosive changes characteristic of seropositive RA.
Table 1 Medical history of Patient 1
Data extracted 25.08.2015
ID Case 1
Age, Gender 68, Female
Work status Pensioner since diagnosis
Diagnosis Rheumatoid Arthritis
Diagnosis criteria - Symptoms: 1.1996
- Clinical diagnosis of RA: 10.1996
Highest RF (IgM) Negative (9) 3.2012
Highest (aCCP) Negative (4) 8.2009
aCarP Negative 7.2015
HLA-B27 Positive
Drug (now) Methotrexate 1.2015
- 7,50 mg Subcutaneous Once a week
Adalimumab (Humira) 1.2015
- 40,00 mg Subcutaneous Every 2. week
Prednisolone 10.2013
- 5,00 mg Peroral Every day
Comorbidity Vertebral fracture 10.2005
Herpes zoster infection 9.2002
Arm fracture, not wrist 8.2001
Osteopenia by DXA 2001
Cholelithiasis 3.1998
Arterial hypertension 11.1996
Fibromyalgia 7.1990
Lumbago/dorsalgia/sciatica 1980
Migraine - Before rheuma diagnosis
Surgery Left ankle Arthrodesis 11.2011
Right ankle Arthrodesis 3.2011
Left MTP Arthrodesis 3.2007
Right MTP Arthrodesis 3.2007
Left knee Arthroplasty 10.2003
Left knee Synovectomy 5.2003
Right knee Arthroscopy and Synovectomy 10.2002
Right knee Rearthroplasty 12.2001
Right knee Arthroplasty 4.1998
Right knee Other surgery 8.1996
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Radiographs of the neck in 2007 indicated a sliding
atlanto axial subluxation of 7 mm in head bending
forward –position. An MRI of the neck showed no
active pannus and no erosions in the dens.
Case 3
Demographics: 63 year old female, diagnosed at the age
of 28 in 05.1980. Cashier, work disabled since September
1989. Never smoked.
Initial presentation: Temporary pains and aches in
knees, wrists, and fingers since the age of 15, and
increasing several months prior to the diagnosis in
05.1980 when she presented with a polyarthritis as
shown in Fig. 3a.
Comorbidities and Joint surgery: See Table 3.
Medications. Current medications are presented in
Table 3. Previous DMARD treatments were (in order):
gold i.m., sulphasalazine, auranofin, hydroxychloroquine,
Fig. 2 a Initial clinical presentation of Patient 2. b Progress of Patient 2. c 1-6. Most recent radiographs of Patient 2 (20-23 years from diagnosis;
neck radiographs in 2007)
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D-penicillamine, azathioprine, podofyllotoxin (Reuma-
con), ciclosporin, cyclophosphamide, chlorambucil, leflu-
nomide, and infliximab (Remicade) see Fig. 3b.
Progress: See Fig. 3b. Most recent values for patient
reported outcomes and disease activity: HAQ 1.38, pain
0, fatigue 0, patient global 0, ESR 33, CRP 10, DAS28 3.0
indicating low disease activity.
Radiographic features: No radiographic joint damage
was seen at initial presentation. The most recent
radiographs 32-35 years after diagnosis are presented
in Fig. 3c and show prominent damage in the, wrists,
ankle/subtalar/upper forefeet areas, as well as status
post orthopaedic surgery in many joints.
Case 4
Demographics: 60 year old female. Diagnosed at the age
of 28 in 12.1982. Waitress, work disabled since 1995,
former smoker.
Initial presentation: Symptoms started two years be-
fore diagnosis, with synovitis in both knees. Two months
prior to diagnosis, symptoms began in other joints
with clinical polyarthritis in 12.1982 as presented in
Fig. 4a.
Comorbidities and Joint surgery: See Table 4.
Treatment: Current medications are presented in
Table 4. Previous DMARD treatments were (in order):
Im gold, sulfasalazine, cyclosporine, infliximab, and
adalimumab, see Fig. 4b.
Progress: See Fig. 4b. Most recent values for patient
reported outcomes and disease activity: HAQ 1.75,
pain 59, fatigue 40, patient global 50, ESR 22, CRP 5,
DAS28 2.9 indication low disease activity.
Radiographic features: The most recent radiographs
of hands, wrists, feet, and ankles, 30-33 years after
diagnosis, are presented in Fig. 4c. Destruction of
wrists and ankle/subtalar area are prominent, with
minimal/no erosions typical for seropositive RA.
Discussion
These cases all share a common feature: that of a
severe, destructive disease in seronegative RA with
involvement primarily of the wrists, sub-talar and
ankle joints, as well as large joints. All these patients
were negative with regard to RF, aCCP, and aCarP.
Two cases were HLA-B27 positive but despite this,
the clinical presentation (signs and symptoms) and
radiographs of the sacro-iliac joints did not support
a diagnosis of ankylosing spondylitis (AS) or other
spondyloarthritides in these individuals.
Seronegative RA has been in focus of only a few
cohorts and rarely in detail, to reveal various aspects
of outcomes [9]. Again, an exception is from the
Heinola group, which reported long-term outcomes of
non-specific seronegative oligoarthritis in patients
with a 23 year follow-up [16]. Based on patient
history, radiographs and clinical status at the follow-
up visit, they re-classified the 64 patients and found
one case each of RA, systemic lupus erythematosus
and ankylosing spondylitis, two cases of post-trau-
matic arthritis, four cases of osteoarthritis, and six cases of
possible reactive arthritis. Of the remaining 49 patients,
15 were HLA-B27 positive and 16 had at least one of the
psoriasis-related HLA antigens. Seven patients had minor
erosions in their hands or feet joints. One HLA-B27 posi-
tive patient had developed bilateral sacroilitis by the
evaluation at 23 years. Functional capacity of the pa-
tients was well retained. Compared to this Heinola
seronegative cohort, our patients present a more se-
vere destructive disease, and to date, remain un-
classified.
To our experience, patients with destructive sero-
negative (RF, aCCP negative) RA - as this disease
entity can be referred to - are rare. Among our
approximately 3000 RA patients, of whom 30 % are
seronegative, only a few seem to present with such
degree of destructive disease. However, over the years
Table 2 Medical history of Patient 2
Data extracted 15.09.2015
ID Case 2
Age, Gender 39, Female
Work status Full-time work
Diagnosis Rheumatoid Arthritis
Diagnosis criteria - Symptoms: 3.1992
- Clinical diagnosis of RA: 7.1992
Highest RF (IgM) Negative (8) 2.2012
Highest (aCCP) Negative (0) 2.2012
aCarP Negative 7.2015
HLA-B27 Negative
Drug (now) Etanercept (Enbrel) 1.2013
- 50,00 mg Subcutaneous Once a week
Methotrexate 5.2011
- 15,00 mg Subcutaneous Once a week
Prednisolone 4.2004
- 5,00 mg Peroral Every day
Comorbidity Neutropenia 12.2012 - 12.2012
Viral infection 12.2012
Osteopenia by bone density by DXA 3.2012
Surgery Neck Arthrodesis 8.2007
Right wrist Tenosynovectomy 10.1995
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it is possible that similar cases have been missed, as
prior to the era of aCCP analyses, a proportion of RF
negative cases demonstrated a typical RF positive
course and were later revealed to be aCCP positive.
Although destructive seronegative RA is rare, it can
have devastating consequences and early recognition
and intensive treatment is paramount.
The current clinical status of the patients presented
in this report indicates considerable functional loss
with a HAQ > 1.5 in three of the four patients.
Despite this, disease activity appears to be under at
least some degree of control with DAS28 values
between 2.1 to 3.4. Current treatment in all four
patients includes prednisolone, methotrexate and
biologic agents (combination of two biologic agents in
Case 4).
The radiological progression of joint damage in
these patients presents major cartilage destruction
and loss and with minor bony erosions of joints. In
fact, it could even be argued that the radiographic
destruction seen in these cases resembles that of
advanced seronegative juvenile polyarthritis.
Conclusions
Through a detailed description of four destructive
seronegative (for RF, aCCP and aCarP) RA cases
from disease-onset and up to 35 years from diagno-
sis, this report could shed more light on the disease
presentation, course and outcomes of such patients.
We hope to inform the reader of this particular sub-
type of inflammatory arthritis which can result in
Fig. 3 a Initial clinical presentation of Patient 3. b Progress of Patient 3. c 1-4. Most recent radiographs of Patient 3 (32-35 years from diagnosis)
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Table 3 Medical history of Patient 3
Data extracted 14.09.2015
ID Case 3
Age, Gender 63, Female
Work status Disabled pensioner since 9.1989
Diagnosis Rheumatoid Arthritis
Diagnosis criteria - Symptoms: 6.1979
- Clinical diagnosis of RA: 5.1980
Highest RF (IgM) Negative (9) 6.2014
Highest (aCCP) Negative (0) 9.2014
aCarP Negative 7.2015
HLA-B27 Negative
Drug (now) Infliximab (Inflectra) 2.2014
- 300,00 mg Intravenous Every 8. week
Prednisolone 2.2011
- 2,50 mg Peroral Every day
Methotrexate 5.2002
- 10,00 mg Peroral Once a week
Comorbidity Hyperlipidemia 4.2011
Hypothyroidism 4.2011
Osteoporosis by DXA 11.1997
Arterial hypertension 6.2011
Surgery Left elbow Prosthesis 2.2011
Right elbow Prosthesis 04.10.2010
Left MCP-1 Arthrodesis 3.2003
Left MCP-4 Prosthesis 3.2003
Left PIP-1 Prosthesis 3.2003
Left PIP-5 Arthrodesis 3.2003
Right DIP-2 Arthrodesis 1.2003
Right MCP-1 Arthrodesis 1.2003
Right MCP-3 Prosthesis 1.2003
Right MCP-4 Prosthesis 1.2003
Right PIP-5 Arthrodesis 1.2003
Right shoulder Prosthesis 12.1997
Left shoulder Prosthesis 9.1997
Right ankle Arthrodesis 9.1996
Right ankle Arthrodesis 1.1996
Left hip Prosthesis 11.1995
Right ankle Arthrodesis 6.1995
Right hip Prosthesis 4.1995
Table 3 Medical history of Patient 3 (Continued)
Left ankle Arthrodesis 5.1994
Right MCP-3 Prosthesis 11.1993
Right MCP-4 Prosthesis 11.1993
Right MCP-5 Prosthesis 11.1993
Right PIP-1 Arthrodesis 11.1993
Left ankle Arthrodesis 3.1993
Right MTP – Joint resection 1990
Left MTP – Joint resection 1990
Right wrist Tenosynovectomy 2.1981
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Fig. 4 a Initial presentation of Patient 4. b Progress of Patient 4. c 1-4. Most recent radiographs of Patient 4 (30-33 years from diagnosis)
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devastating patient outcomes and therefore needs
prompt identification and treatment, similar to
seropositive disease. This report justifies the under-
taking of further research on the pathogenesis and
identification of possible biomarkers for this type of
arthropathy, which could be invaluable in firstly
understanding disease behavior and course and
secondly in treatment stratification.
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